Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390677 | 0.80 | TDP1 (0.36) | ERN1LMNATRIM24TRIM33 | |
| SCHEMBL898807 | 0.80 | TDP1 (0.36) | ERN1LMNATRIM24TRIM33 | |
| SCHEMBL27176134 | 0.80 | ERN1 (0.48) | ERN1TLR2TLR1TLR6LMNA | |
| SCHEMBL31117136 | 0.79 | LMNA (0.36) | LMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL29715811 | 0.78 | ERN1 (0.63) | ERN1 | |
| SCHEMBL8608798 | 0.78 | ERN1 (0.47) | ERN1TLR2TLR1TLR6LMNA | |
| SCHEMBL1042430 | 0.78 | ERN1 (0.63) | ERN1 | |
| SCHEMBL12814036 | 0.78 | ERN1 (0.52) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL31114189 | 0.78 | ERN1 (0.52) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL25385131 | 0.75 | ERN1 (0.50) | ERN1TLR2TLR1TLR6TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4682141-A1 | TRICYCLIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2026-01-21 | — | — | EP | disclosed |
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025072392-A1 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-3805231-B1 | INHIBITOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-113227101-B | Salt or crystal form containing tricyclic derivative and pharmaceutical composition thereof | 上海翰森生物医药科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024192309-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024190780-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR KIDNEY DISEASES CONTAINING TRICYCLIC COMPOUND | 小野薬品工業株式会社 | 2024-09-19 | — | — | WO | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3055309-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | Takeda Pharmaceutical Company Limited (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| WO-2015052910-A1 | ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | WO | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | ERN1 829/4885TLR2 4231/4885TLR1 3925/4885 |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | ERN1 3408/4885TLR2 855/4885TLR1 717/4885 |
| US-20160237087-A1 | HETEROCYCLIC COMPOUNDS | SSTR5, SSTR4, SSTR2 | ERN1 3437/4885TLR2 857/4885TLR1 721/4885 |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | ERN1 3448/4885TLR2 859/4885TLR1 719/4885 |
| US-12624050-B2 | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof | OGDH, ME1, GCDH | ERN1 3645/4885TLR2 1061/4885TLR1 908/4885 |
| US-12630561-B2 | Tricyclic derivatives inhibitor, preparation method, and applications thereof | PIK3CA, PIK3R1, PIK3CD | ERN1 1001/4885TLR2 3502/4885TLR1 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.